Detection of NDM Variants (blaNDM-1, blaNDM-2, blaNDM-3) from Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae: First Report from Nepal
Anisha Thapa,Milan Kumar Upreti,Nabin Kishor Bimali,Basudha Shrestha,Anil Kumar Sah,Krishus Nepal,Binod Dhungel,Sanjib Adhikari,Nabaraj Adhikari,Binod Lekhak,Komal Raj Rijal
DOI: https://doi.org/10.2147/IDR.S369934
2022-08-11
Infection and Drug Resistance
Abstract:Anisha Thapa, 1, &ast Milan Kumar Upreti, 1, &ast Nabin Kishor Bimali, 1 Basudha Shrestha, 2 Anil Kumar Sah, 3 Krishus Nepal, 1 Binod Dhungel, 4 Sanjib Adhikari, 4 Nabaraj Adhikari, 4 Binod Lekhak, 1, 4 Komal Raj Rijal 4 1 Department of Microbiology, Golden Gate International College, Kathmandu, Nepal; 2 Kathmandu Model Hospital, Kathmandu, Nepal; 3 Annapurna Neurological Institute and Allied Sciences, Kathmandu, Nepal; 4 Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal &astThese authors contributed equally to this work Correspondence: Komal Raj Rijal, Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal, Email Background: Increasing burden of carbapenem resistance among Enterobacterales is attributable to their ability to produce carbapenemase enzymes like metallo-beta-lactamase (MBL), Klebsiella pneumoniae carbapenemase (KPC), and OXA-type. This study aimed to determine the prevalence of carbapenemases and MBL genes (( bla NDM-1, bla NDM-1 and bla NDM-3 ) among E. coli and K. pneumoniae isolates. Methods: A total of 2474 urine samples collected during the study period (July–December 2017) were processed at the microbiology laboratory of Kathmandu Model Hospital, Kathmandu. Isolates of E. coli and K. pneumoniae were processed for antimicrobial susceptibility testing (AST) by disc diffusion method. Carbapenem-resistant isolates were subjected to Modified Hodge Test (MHT) for phenotypic confirmation, and inhibitor-based combined disc tests for the differentiation of carbapenemase (MBL and KPC). MBL-producing isolates were screened for NDM genes by polymerase chain reaction (PCR). Results: Of the total urine samples processed, 19.5% (483/2474) showed the bacterial growth. E. coli (72.6%; 351/483) was the predominant isolate followed by K. pneumoniae (12.6%; 61/483). In AST, 4.4% (18/412) isolates of E. coli (15/351) and K. pneumonia (3/61) showed resistance towards carbapenems, while 1.7% (7/412) of the isolates was confirmed as carbapenem-resistant in MHT. In this study, all (3/3) the isolates of K. pneumoniae were KPC-producers, whereas 66.7% (10/15), 20% (3/15) and 13.3% (2/15) of the E. coli isolates were MBL, KPC and MBL/KPC (both)-producers, respectively. In PCR assay, 80% (8/10), 90% (9/10) and 100% (10/10) of the isolates were positive for bla NDM-1 , bla NDM-2 and bla NDM-3, respectively. Conclusion: Presence of NDM genes among carbapenemase-producing isolates is indicative of potential spread of drug-resistant variants. This study recommends the implementation of molecular diagnostic facilities in clinical settings for proper infection control, which can optimize the treatment therapies, and curb the emergence and spread of drug-resistant pathogens. Keywords: E. coli , K. pneumoniae , MBL, KPC, NDM variants Gram-negative bacteria, especially those falling under the family Enterobacterales (eg, Escherichia, Klebsiella , and Enterobacter ) as well as pseudomonads and Acinetobacter serve as the potential pathogens in nosocomial and community-acquired infections in urinary and respiratory tracts, blood stream, intra-abdominal and surgical site infections. 1,2 Some of these Gram-negative bacilli are also included in ESKAPE—a group of six nosocomial pathogens ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.) that are notorious for drug resistance and virulence. 3 Among those species, Escherichia coli and Klebsiella spp., are the most frequently reported pathogens in developing countries with poor health care system. 4 Antibiotics are the empirical choice of treatment to counter such pathogenic strains of bacteria. However, despite the advent of effective antibiotic therapy, bacteria are constantly evolving noble mechanisms to evade the treatment regimen in question, giving rise to the global problem of antimicrobial resistance (AMR)—a condition in which pathogenic bacteria develop resistance to specific antibiotics to which they were at first sensitive. 5 Infection management becomes even more onerous once a pathogenic strain develops multidrug resistance (MDR)—resistance towards at least one antimicrobial drug in three or more antimicro -Abstract Truncated-
pharmacology & pharmacy,infectious diseases